experts in multiple disciplines to share best practices on leveraging AI in
clinical settings


NASHUA, N.H. – September 9, 2020 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader
providing innovative cancer detection and therapy solutions, today announced it
host a free virtual roundtable event for
clinicians, titled “What is Real AI: Adopting Artificial Intelligence,” on September
15, 2020 at 7 pm ET/4 pm PT. Event registration is available via
this link: https://register.gotowebinar.com/register/1600095491848475917.


“This unique event
provides a rare opportunity to learn from leading experts in multiple
disciplines hailing from influential companies focused on the criteria for
making AI decisions in clinical settings to enhance patient care,” according to
Stacey Stevens, President of iCAD, Inc. “As we have seen with the commercial
success of ProFound AI following its FDA-clearance in December 2018, demand
continues to grow for clinically proven solutions that can streamline workflow
and improve outcomes. In recent months the COVID-19 pandemic has severely
impacted cancer screening – for many types of cancer, including breast – further
underscoring the need for clinicians to be educated about the latest
innovations that can increase accuracy and efficiency, which may help to manage
the backlog of patients who need to be screened. We are pleased to host this
educational event, and to provide a forum for clinicians to learn about the
latest in AI technology so they may make more informed decisions with knowledge
of the appropriate evaluation criteria when adopting AI technology into their


The roundtable will
feature specialists in AI and cancer
including the following leading experts*:

  • Grant Davies, CEO, Solis Mammography (panelist)
  • Randy Hicks,
    MD, MBA, Co-owner and CEO of Regional Medical Imaging (panelist)
  • Senthil Periaswamy, PhD, Chief Research Scientist, VP of Clinical Innovation, iCAD, Inc. (panelist)
  • Greg Sorensen, MD, CEO and Co-founder of DeepHealth, Inc. (panelist)
  • Lawrence Tanenbaum,
    MD, CTO, Director of Advanced Imaging, VP, Radnet Inc. (panelist)
  • Susan Wood, PhD,
    President and CEO, VIDA (moderator)

During the event,
panelists will discuss the latest AI solutions for cancer screening and the
benefits AI technology offers to clinicians and patients alike. The goal of
this event is to educate clinicians about the value of AI in clinical practice,
in the era of COVID-19 and moving forward.


“COVID-19 has laid bare
the fragmentation in our healthcare system while highlighting the potential for
AI and digital solutions to help us emerge from this crisis. This
event will deliver valuable insights about cancer screenings during
COVID-19 and address how AI can help clinicians navigate these unchartered
waters,” according to Dr. Wood. “We are in a rapidly changing market and
events like this can help the medical community synthesize a vast amount
of information so clinicians make educated decisions when adopting new
technology that can ultimately enhance patient care.” 


This virtual roundtable event is a part
of a larger series of webinars hosted by iCAD in recent months.  Previous events featured leading experts in
breast cancer detection and treatment, and have examined various aspects of
breast cancer care in the era of COVID-19, including risk-adaptive tools and
pragmatic solutions for both screening and treatment. To register for an
upcoming free event or view a prior event on-demand, visit


*Panelists have been
compensated with an honoraria/speaking fee, but are encouraged to provide their
own expert opinions and viewpoints. Dr. Wood is a member of iCAD’s Board of


About iCAD, Inc.


in Nashua, NH, iCAD is a global medical technology
leader providing innovative cancer detection and therapy solutions.


ProFound AI™ is a high-performing workflow solution for 2D and 3D
mammography, or digital breast tomosynthesis (DBT), featuring the latest in
deep-learning artificial intelligence. In 2018, ProFound AI for Digital Breast
Tomosynthesis (DBT) became the first artificial intelligence (AI) software for
DBT to be FDA-cleared; it was also CE marked and Health Canada licensed that
same year. It offers clinically proven time-savings benefits to radiologists,
including a reduction of reading time by 52.7 percent, thereby halving the
amount of time it takes radiologists to read 3D mammography datasets.
Additionally, ProFound AI for DBT improved radiologist sensitivity by 8 percent
and reduced unnecessary patient recall rates by 7.2 percent.[i]


The Xoft System is FDA-cleared, CE
marked and licensed in a growing number of countries for the treatment of
cancer anywhere in the body. It uses a proprietary miniaturized x-ray source to
deliver a precise, concentrated dose of radiation directly to the tumor site,
while minimizing risk of damage to healthy tissue in nearby areas of the body.


For more information, visit www.icadmed.com and www.xoftinc.com.


Forward-Looking Statements

Certain statements contained in this News Release constitute
“forward-looking statements” within the meaning of the Private Securities
Litigation Reform Act of 1995, including statements about the future prospects
for the Company’s technology platforms and products. Such forward-looking
statements involve a number of known and unknown risks, uncertainties and other
factors which may cause the actual results, performance or achievements of the
Company to be materially different from any future results, performance or
achievements expressed or implied by such forward-looking statements. Such
factors include, but are not limited, to the Company’s ability to achieve
business and strategic objectives, the willingness of patients to undergo
mammography screening in light of risks of potential exposure to Covid-19,
whether mammography screening will be treated as an essential procedure,
whether ProFound AI will improve reading efficiency, improve specificity and
sensitivity, reduce false positives and otherwise prove to be more beneficial
for patients and clinicians,  the impact
of supply and manufacturing constraints or difficulties on our ability to
fulfill our orders, uncertainty of future sales levels, to defend itself in
litigation matters, protection of patents and other proprietary rights,  product market acceptance, possible technological
obsolescence of products, increased competition, government regulation, changes
in Medicare or other reimbursement policies, risks relating to our existing and
future debt obligations, competitive factors, the effects of a decline in the
economy or markets served by the Company; and other risks detailed in the
Company’s filings with the Securities and Exchange Commission. The words
“believe,” “demonstrate,” “intend,” “expect,” “estimate,” “will,” “continue,”
“anticipate,” “likely,” “seek,” and similar expressions identify forward-looking
statements. Readers are cautioned not to place undue reliance on those
forward-looking statements, which speak only as of the date the statement was
made. The Company is under no obligation to provide any updates to any
information contained in this release. For additional disclosure regarding
these and other risks faced by iCAD, please see the disclosure contained in our
public filings with the Securities and Exchange Commission, available on the
Investors section of our website at www.icadmed.com and on the SEC’s
website at http://www.sec.gov.




Media inquiries:

Jessica Burns, iCAD  




Investor Relations:

Jeremy Feffer,
LifeSci Advisors





[i] Conant, E.
et al. (2019). Improving Accuracy and Efficiency with Concurrent Use of
Artificial Intelligence for Digital Breast Tomosynthesis. Radiology: Artificial
Intelligence. 1 (4). Accessed via